Cellular restoration in HIV infected persons treated with abacavir and a protease inhibitor: age inversely predicts naive CD4 cell count increase

被引:71
作者
Lederman, MM
McKinnis, R
Kelleher, D
Cutrell, A
Mellors, J
Neisler, M
Cooney, E
Haas, DW
Haubrich, R
Stanford, J
Horton, J
Landay, A
Spreen, W
机构
[1] Univ Hosp Cleveland, Cleveland, OH 44106 USA
[2] Case Western Reserve Univ, Sch Med, Cleveland, OH USA
[3] Dreams du Jour Inc, Point Harbor, NC USA
[4] Glaxo Wellcome Inc, Res Triangle Pk, NC 27709 USA
[5] Univ Pittsburgh, Pittsburgh, PA USA
[6] Covance Inc, Indianapolis, IN USA
[7] Yale Univ, New Haven, CT USA
[8] Vanderbilt Univ, Nashville, TN USA
[9] Univ Calif San Diego, San Diego, CA 92103 USA
[10] Kansas City AIDS Res Consortium, Kansas City, MO USA
[11] Carolinas Med Ctr, Charlotte, NC 28203 USA
[12] Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA
关键词
anitretroviral therapy; immune reconstitution; CD4; CD8; CD28; cellular immunity; protease inhibitors; reverse transcriptase inhibitors;
D O I
10.1097/00002030-200012010-00002
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To characterize early and later indices of cellular restoration among HIV-1 infected persons treated with abacavir and one protease inhibitor and to identify predictors of CD4 cell increases. Methods: Flow-cytometric analyses of lymphocyte phenotypes among 71 antiretroviral treatment naive adults in a 48 week treatment trial. Results: During the first 4 weeks of therapy, increases in naive and memory CD4 cells and in B cells were seen; naive CD8 cells increased while CD8 cells remained stable as memory CD8 cells decreased. During the second phase total CD4 and naive CD4 and CD8 cells increased while total CD8 and memory CD8 cells decreased. The numbers of CD4 cells that expressed CD28 increased from a median of 308 x 10(6)/l at baseline to 477 x 10(6)/l at week 48. Higher baseline plasma HIV-1 RNA levels predicted the magnitude of early CD4 ( r = 0.35; P = 0.01), memory CD4 (r = 0.38; P = 0.001) and CD28 CD4 cell (r = 0.29; P = 0.01) restoration but was not related to second phase changes. Younger age predicted a greater second phase (but not first phase) increase in naive CD4 cells (r = -0.31; P = 0.03). Conclusions: Higher baseline levels of HIV-1 replication determine the magnitude of first phase CD4 cell increases after suppression of HIV-1 replication. Second phase (primarily naive) CD4 cell increases are not related to HIV-1 replication but are inversely relate to age suggesting that thymic potential is a major determinant of long term cellular restoration in HIV-1 infected persons receiving antiretroviral therapy. (C) 2000 Lippincott Williams & Wilkins.
引用
收藏
页码:2635 / 2642
页数:8
相关论文
共 32 条
  • [1] Tumor necrosis factor (TNF) system levels in human immunodeficiency virus-infected patients during highly active antiretroviral therapy:: Persistent TNF activation is associated with virologic and immunologic treatment failure
    Aukrust, P
    Müller, F
    Lien, E
    Nordoy, I
    Liabakk, NB
    Kvale, D
    Espevik, T
    Froland, SS
    [J]. JOURNAL OF INFECTIOUS DISEASES, 1999, 179 (01) : 74 - 82
  • [2] Positive effects of combined antiretroviral therapy on CD4(+) T cell homeostasis and function in advanced HIV disease
    Autran, B
    Carcelain, G
    Li, TS
    Blanc, C
    Mathez, D
    Tubiana, R
    Katlama, C
    Debre, P
    Leibowitch, J
    [J]. SCIENCE, 1997, 277 (5322) : 112 - 116
  • [3] In vivo analysis of Fas/FasL interactions in HIV-infected patients
    Badley, AD
    Dockrell, DH
    Algeciras, A
    Ziesmer, S
    Landay, A
    Lederman, MM
    Connick, E
    Kessler, H
    Kuritzkes, D
    Lynch, DH
    Roche, P
    Yagita, H
    Paya, CV
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1998, 102 (01) : 79 - 87
  • [4] Initial increase in blood CD4+ lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues
    Bucy, RP
    Hockett, RD
    Derdeyn, CA
    Saag, MS
    Squires, K
    Sillers, M
    Mitsuyasu, RT
    Kilby, JM
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (10) : 1391 - 1398
  • [5] Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease
    Cameron, DW
    Heath-Chiozzi, M
    Danner, S
    Cohen, C
    Kravcik, S
    Maurath, C
    Sun, E
    Henry, D
    Rode, R
    Potthoff, A
    Leonard, J
    [J]. LANCET, 1998, 351 (9102) : 543 - 549
  • [6] Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response
    Connick, E
    Lederman, MM
    Kotzin, BL
    Spritzler, J
    Kuritzkes, DR
    St Clair, M
    Sevin, AD
    Fox, L
    Chiozzi, MH
    Leonard, JM
    Rousseau, F
    Roe, JD
    Martinez, A
    Kessler, H
    Landay, A
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (01) : 358 - 363
  • [7] Effects of subcutaneous interleukin-2 therapy on CD4 subsets and in vitro cytokine production in HIV plus subjects
    De Paoli, P
    Zanussi, S
    Simonelli, C
    Bortolin, MT
    D'Andrea, M
    Crepaldi, C
    Talamini, R
    Comar, M
    Giacca, M
    Tirelli, U
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1997, 100 (11) : 2737 - 2743
  • [8] Changes in thymic function with age and during the treatment of HIV infection
    Douek, DC
    McFarland, RD
    Keiser, PH
    Gage, EA
    Massey, JM
    Haynes, BF
    Polis, MA
    Haase, AT
    Feinberg, MB
    Sullivan, JL
    Jamieson, BD
    Zack, JA
    Picker, LJ
    Koup, RA
    [J]. NATURE, 1998, 396 (6712) : 690 - 695
  • [9] Effect of HIV on thymic function before and after antiretroviral therapy in children
    Douek, DC
    Koup, RA
    McFarland, RD
    Sullivan, JL
    Luzuriaga, K
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2000, 181 (04) : 1479 - 1482
  • [10] Sex differences in HIV-1 viral load and progression to AIDS
    Farzadegan, H
    Hoover, DR
    Astemborski, J
    Lyles, CM
    Margolick, JB
    Markham, RB
    Quinn, TC
    Vlahov, D
    [J]. LANCET, 1998, 352 (9139) : 1510 - 1514